Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pittock, Sean J, Fujihara, Kazuo, Palace, Jacqueline, Berthele, Achim, Kim, Ho Jin, Oreja-Guevara, Celia, Nakashima, Ichiro, Levy, Michael, Shang, Shulian, Yountz, Marcus, Miller, Larisa, Armstrong, Róisín, Wingerchuk, Dean M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894682/
https://www.ncbi.nlm.nih.gov/pubmed/34498507
http://dx.doi.org/10.1177/13524585211038291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894682/
https://www.ncbi.nlm.nih.gov/pubmed/34498507
http://dx.doi.org/10.1177/13524585211038291

Ejemplares similares